Vascular endothelial function assessed by a noninvasive ultrasound method and serum asymmetric dimethylarginine concentrations in mild-to-moderate plaque-type psoriatic patients

Clinical Biochemistry

Volumn 44, Issue 13, 2011, Pages 1080-1084

  Usta, Murat ^a   Yurdakul, Selen ^b   Aral, Hale ^c   Turan, Enver ^d   Oner, Ender ^e   Inal, Berrin Bercik ^c   Oner, Fatma Alibaz ^f   Gurel, Mehmet Salih ^c   Guvenen, Guvenc ^c  

^a Ministry of Health Sivas Numune Hospital   (Turkey)

^b FLORENCE NIGHTINGALE HOSPITAL   (Turkey)

^c ISTANBUL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d Ministry of Health Batman Regional Government Hospital   (Turkey)

^e ISTANBUL MEHMET AKIF ERSOY THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^f MARMARA UNIVERSITY   (Turkey)

Author keywords

Brachial artery; Dimethylarginine; Endothelium; Psoriasis

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; GLYCERYL TRINITRATE; N(G),N(G) DIMETHYLARGININE;

ADULT; ARTICLE; BLOOD VESSEL PARAMETERS; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; FIBRINOGEN BLOOD LEVEL; FLOW MEDIATED DILATATION; HUMAN; HUMAN TISSUE; LIPID BLOOD LEVEL; MALE; NITROGLYCERIN INDUCED DILATATION; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; PSORIASIS VULGARIS; ULTRASOUND SCANNER; VASODILATATION;

ACUTE-PHASE PROTEINS; ADULT; ARGININE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOGEN; HUMANS; MALE; PSORIASIS; SEVERITY OF ILLNESS INDEX; VASODILATION;

EID: 80051684628     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.06.007     Document Type: Article

References (42)

1. Brunner H., Cockcroft J.R., Deanfield J., Donald A., Ferrannini E., Halcox J., et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005, 23:233-246.
2. Nadar S., Blann A.D., Lip G.Y. Endothelial dysfunction: methods of assessment and application to hypertension. Curr Pharm Des 2004, 10:3591-3605.
3. Schächinger V., Britten M.B., Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000, 101:1899-1906.
4. Schnabel R., Blankenberg S., Lubos E., Lackner K.J., Rupprecht H.J., Espinola-Klein C., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005, 97:e53-e59.
5. Miyazaki H., Matsuoka H., Cooke J.P., Usui M., Ueda S., Okuda S., et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999, 99:1141-1146.
6. Späh F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 2008, 159:10-17.
7. Wakkee M., Thio H.B., Prens E.P., Sijbrands E.J., Neumann H.A. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007, 190:1-9.
8. Gisondi P., Tessari G., Conti A., Piaserico S., Schianchi S., Peserico A., et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007, 157:68-73.
9. Sommer D.M., Jenisch S., Suchan M., Christophers E., Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006, 298:321-328.
10. Langley R.G., Ellis C.N. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004, 51:563-569.
11. Naldi L., Gambini D. The clinical spectrum of psoriasis. Clin Dermatol 2007, 25:510-518.
12. Freidewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
13. Schulze F., Wesemann R., Schwedhelm E., Sydow K., Albsmeier J., Cooke J.P., et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004, 42:1377-1383.
14. Schulze F., Maas R., Freese R., Schwedhelm E., Silberhorn E., Böger R.H. Determination of a reference value for N(G), N(G)-dimethyl-l-arginine in 500 subjects. Eur J Clin Invest 2005, 35:622-626.
15. Celermajer D.S., Adams M.R., Clarkson P., Robinson J., McCredie R., Donald A., et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 1996, 334:150-154.
16. Huang P.H., Chen J.W., Lu T.M., Yu-An Ding P., Lin S.J. Combined use of endothelial function assessed by brachial ultrasound and high-sensitive C-reactive protein in predicting cardiovascular events. Clin Cardiol 2007, 30:135-140.
17. Gornik H.L., Creager M.A. Arginine and endothelial and vascular health. J Nutr 2004, 134:2880S-2887S.
18. Melikian N., Wheatcroft S.B., Ogah O.S., Murphy C., Chowienczyk P.J., Wierzbicki A.S., et al. Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young Black African men. Hypertension 2007, 49:873-877.
19. Tziomalos K., Athyros V.G., Karagiannis A., Mikhailidis D.P. Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutr Metab Cardiovasc Dis 2010, 20:140-146.
20. Griffiths C.E., Dubertret L., Ellis C.N., Finlay A.Y., Finzi A.F., Ho V.C., et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004, 150(Suppl 67):11-23.
21. Katz H.I., Waalen J., Leach E.E. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 1999, 41:S7-S12.
22. Dierkes J., Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med 2005, 5:124-139.
23. Azfar R.S., Gelfand J.M. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 2008, 20:416-422.
24. Laurent M.R., Panayi G.S., Shepherd P. Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis 1981, 40:66-69.
25. Coimbra S., Oliveira H., Reis F., Belo L., Rocha S., Quintanilha A., et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol 2010, 24:789-796.
26. Chodorowska G., Wojnowska D., Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol 2004, 18:180-183.
27. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
28. Balci D.D., Balci A., Karazincir S., Ucar E., Iyigun U., Yalcin F., et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol 2009, 23:1-6.
29. Ulusoy R.E., Karabudak O., Yokusoglu M., Kilicaslan F., Kirilmaz A., Cebeci B.S. Noninvasive assessment of impaired endothelial function in psoriasis. Rheumatol Int 2010, 30:479-483.
30. Uittenbogaard A., Shaul P.W., Yuhanna I.S., Blair A., Smart E.J. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 2000, 275:11278-11283.
31. Li X.P., Zhao S.P., Zhang X.Y., Liu L., Gao M., Zhou Q.C. Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int J Cardiol 2000, 73:231-236.
32. Myers P.R., Parker J.L., Tanner M.A., Adams H.R. Effects of cytokines tumor necrosis factor alpha and interleukin 1 beta on endotoxin-mediated inhibition of endothelium-derived relaxing factor bioactivity and nitric oxide production in vascular endothelium. Shock 1994, 1:73-78.
33. Wang P., Ba Z.F., Chaudry I.H. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol 1994, 266:H2535-H2541.
34. Cleland S.J., Sattar N., Petrie J.R., Forouhi N.G., Elliott H.L., Connell J.M. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) 2000, 98:531-535.
35. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002, 106:1439-1441.
36. Hardie K.L., Kinlay S., Hardy D.B., Wlodarczyk J., Silberberg J.S., Fletcher P.J. Reproducibility of brachial ultrasonography and flow-mediated dilatation (FMD) for assessing endothelial function. Aust N Z J Med 1997, 27:649-652.
37. Corretti M.C., Plotnick G.D., Vogel R.A. The effects of age and gender on brachial artery endothelium-dependent vasoactivity are stimulus-dependent. Clin Cardiol 1995, 18:471-476.
38. Blackwell S., O'Reilly D.S., Talwar D. Biological variation of asymmetric dimethylarginine and related arginine metabolites and analytical performance goals for their measurement in human plasma. Eur J Clin Invest 2007, 37:364-371.
39. Meinitzer A., Puchinger M., Winklhofer-Roob B.M., Rock E., Ribalta J., Roob J.M., et al. Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method. Clin Chim Acta 2007, 384:141-148.
40. Sydow K., Fortmann S.P., Fair J.M., Varady A., Hlatky M.A., Go A.S., et al. ADVANCE Investigators. Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin Chem 2010, 56:111-120.
41. Caussé E., Siri N., Arnal J.F., Bayle C., Malatray P., Valdiguié P., et al. Determination of asymmetrical dimethylarginine by capillary electrophoresis-laser-induced fluorescence. J Chromatogr B Biomed Sci Appl 2000, 741:77-83.
42. Schwedhelm E., Tan-Andresen J., Maas R., Riederer U., Schulze F., Böger R.H. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 2005, 51:1268-1271.